Table II.
Serologic Assays for Alpha-gal in Selected Vaccines
| A: IgE binding (kU/ml) to biotinylated vaccines assayed with alpha-gal positive sera from three subjects, with and without bovine thyroglobulin (BT) to deplete alpha gal IgE | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TDaP (Sanofi) | TDaP (GSK) | MMR | Yellow Fever | Zoster | Gelatin Immunocap c74 | ||||||
|
Trial 1 |
Trial 2 |
Trial 1 |
Trial 2 |
Trial 1 |
Trial 2 |
Trial 1 |
Trial 2 |
Trial 1 |
Trial 2 |
Baseline | |
| Index Patient | <0.1 | 0.11 | <0.1 | <0.1 | 1.31 | 1.22 | 0.27 | 0.25 | 1.14 | 0.96 | 0.16 |
| w/BT Beads | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | 0.13 | <0.1 | <0.1 | |
| Subject A | 0.10 | 0.11 | 0.11 | <0.1 | 0.27 | 0.28 | 0.41 | 0.37 | 0.34 | 0.35 | <0.1 |
| w/BT Beads | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | 0.39 | 0.40 | <0.1 | <0.1 | |
| Subject B | 1.28 | 1.43 | 1.06 | 1.63 | 1.46 | 1.16 | 0.90 | 1.18 | 1.04 | 1.16 | 0.72 |
| w/BT Beads | 1.06 | 1.30 | 1.22 | 1.20 | 1.05 | 0.91 | 0.90 | 1.12 | 0.60 | 0.76 | |
| Subject C | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 |
| w/BT Beads | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | |
| B: Serum alpha-gal IgE (kU/ml) levels at baseline and after overnight incubation with vaccines and gelatins | ||||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | TDaP (Sanofi) | TDaP (GSK) | MMR | Yellow Fever | Zoster | Porcine Gelatin | Bovine Gelatin | |
| Index Patient | 58.3 | 55.9 | 57.8 | 31.2 | 56.9 | 33.1 | 54.7 | 56.6 |
| Subject A | >100 | >100 | >100 | 0.96 | >100 | 91.4 | >100 | >100 |
| Subject B | >100 | >100 | >100 | 71.5 | 87.6 | 83.3 | 94.6 | 97.3 |
| Subject C | 84.4 | 72.6 | 86.9 | 60.7 | 75.7 | 56 | 82.8 | 81 |
BT= Bovine Thyroglobulin. All values are in units of kU/mL.
All values in units of kU/mL). Baseline values are the patient’s serum alpha-gal IgE values prior to overnight incubation.